**ATMP**
Advanced Therapy Medicinal Product

**collaborative project in WALLONIA**

**3 Pillars**
12 work packages

**Gene Therapy**

- Neurodegenerative and eye diseases
- Liver, lungs, and cardiovascular diseases
- Genetic and rare diseases
- Autoimmune and inflammatory diseases
- Metabolic diseases
- Bone and musculoskeletal diseases
- Cancers

**Cell Therapy**

**Exosomes & Phagotherapy**

**Wallonia Value chain**

- Supported by many private & public investors
- Highly competent regulatory and reimbursement authorities
- Diversified ecosystem where all ATMP aspects are represented:
  - Regional clustering of life science players active all along the ATMP value chain: academic, hospitals, biotechs, large groups, service providers and CDMOs.
  - This network is unique in Europe.
  - World-renowned footprint and expertise legacy in biomedicines manufacturing facilities.

**Expected economic impact**

- Regional attractiveness
- Exportations
- Companies added value
- Jobs
  - 5 years forecast
  - 1800 direct & indirect jobs linked to ATMPs

**Expected societal impact**

- Treatment of serious diseases previously incurable such as cancers, genetic diseases
- Personalized therapy increasing efficacy decreasing side effects
- Less chronic diseases reducing costs at long-term

**Expected environmental impact**

- Most ATMPs are bio-sourced
- Less dependence on chemical processes
- Alternative to chemotherapeutic treatments
- Reducing toxic environment contamination

**21 Companies**

**4 Universities**
academic hospitals

**1 Accredited Research**